AngioDynamics has filed a lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of ...

AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.

COLONIE — Latham's AngioDynamics is alleging that a major competitor in the medical device market, C.R. Bard, is violating anti-trust laws in the sale of its catheters. In a lawsuit filed in U.S.

The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence The ALPHA-PE Research Fund is designed to support independent, physician-led research ...

Q4 sales grew 13% year over year, although gross profit margins on those sales declined by 160 basis points, to 52.7%. Adjusted earnings still ended up better than expected, and AngioDynamics cut its ...

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release. The company’s BioFlo peripherally inserted central catheters ...

Shares of AngioDynamics (ANGO) have gained 4.3% over the past four weeks to close the last trading session at $10.86, but there could still be a solid upside left in the stock if short-term price ...

Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...